Medivir AB (LTS:0GP7) Growth Rank: 6 (As of Sep. 11, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GP7 Medivir AB LTS:0GP7
61 GF Score
Price kr1.91
GF Value kr1.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Growth Rank?

Medivir AB LTS:0GP7 61 Growth Rank is 6 as of Sep. 11, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates LTS:0GP7 with a GF Score™ of 61/100 and a GF Value™ of kr1.24 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Medivir AB has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

LTS:0GP7 vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Medivir AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Medivir AB's Growth Rank falls into.


LTS:0GP7
61GF Score
Medivir AB LTS:0GP7
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Medivir AB (LTS:0GP7) has a Growth Rank of 6 as of Sep. 11, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medivir AB and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Medivir AB's Growth Rank has ranged from 1.00 to 7.00.
Is Medivir AB's Growth Rank too high?
Medivir AB's current Growth Rank of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, Medivir AB has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Growth Rank compare to VRTX and REGN?
Medivir AB's Growth Rank of 6 can be compared against companies in the Biotechnology industry. Historically, Medivir AB's own Growth Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medivir AB and its competitors. Medivir AB's current Growth Rank is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.91 — trading 54% above its estimated fair value. The current Growth Rank is 6, which is 50% above median its 10-year median of 4.00. Medivir AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Growth Rank is 6 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (LTS:0GP7) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.91 is trading 54% above its estimated GF Value™ of kr1.24. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for LTS:0GP7:

  • Growth Rank: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: kr1.24 vs. price of kr1.91 (54% above fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
61GF Score

Get the complete analysis for LTS:0GP7

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.91
Price
kr1.24
GF Value